| Orginal Article |
|
|
|
|
| Detection and the Clinical Significance of Molecular Markers in the Diagnosis and Treatment of Leukemia |
| QIN Ya-zhen |
| Peking University People’s Hospital, Peking University Institute of Hematology,National Clinical Research Center for Hematologic Disease, Beijing 100044, China |
|
|
|
Abstract Precision treatment is the present therapeutic strategy to leukemia, and accurate diagnosis and prognostic stratification is the basis. At present, leukemia typing is based on the combination of morphology, immunotyping, cytogenetics and molecular biology. In the past decades, due to the identification of a lot of new molecular abnormalities, molecular detection is becoming more and more important in the diagnosis and treatment of leukemia. The basic techniques for molecular detection are PCR and sequencing. The common leukemia related molecular markers include fusion gene, gene mutation and gene overexpression, and they have shown important clinical significances in the diagnosis, the selection of target therapy, the monitoring of measurable residual disease (MRD) and prognosis.
|
|
Received: 22 August 2019
Published: 20 September 2019
|
|
|
|
|
| [1] |
Baccarani M, Deininger MW, Rosti G , et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood, 2013,122(6):872-884.
doi: 10.1182/blood-2013-05-501569
|
|
|
| [2] |
D?hner H, Estey E, Grimwade D , et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood, 2017,129(4):424-447.
|
|
|
| [3] |
Tallman M S, Wang E S, Altman J K , et al. Acute myeloid leukemia, Version 3.2019, NCCN clinical practice guidelines in oncology. Journal of National Comprehensive Cancer Network, 2019,17(6):721-749.
|
|
|
| [4] |
中华医学会血液学分会实验诊断学组, 中国慢性髓性白血病联盟专家组. 中国慢性髓性白血病诊疗监测规范(2014年版). 中华血液学杂志, 2014,35(8):781-784.
|
|
|
| [4] |
Chinese Society of Hematology, Chinese Medical Association, Chinese CML Committee . Guideline for the diagnosis and management in the disease monitoring of patients with chronic myeloid leukemia in China (2014). Chinese Journal of Hematology, 2014,35(8):781-784.
|
|
|
| [5] |
中华医学会血液学分会白血病淋巴瘤学组. 成人急性髓系白血病(非急性早幼粒细胞白血病)中国诊疗指南(2017年版). 中华血液学杂志, 2017,38(3):177-182.
|
|
|
| [5] |
Leukemia & Lymphoma Group, Chinese Society of Hematology, Chinese Medical Association . Chinese guidelines for diagnosis and treatment of adult acute myeloid leukemia (not APL)(2017). Chinese Journal of Hematologyi, 2017,38(3):177-182.
|
|
|
| [6] |
秦亚溱, 黄晓军 . 新一代检测技术在白血病精准医疗中的应用及挑战. 中华血液学杂志, 2019,40(5):353-357.
|
|
|
| [6] |
Qin Y Z, Huang X J . Application and challenges of the new generation detection technologies in precision medicine for leukemia, Chinese Journal of Hematology, 2019,40(5):353-357.
|
|
|
| [7] |
Thiede C, Koch S, Creutzig E , et al. Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML). Blood, 2006,107(10):4011-4020.
|
|
|
| [8] |
Hoffbrand A V, Higgs D R, Keeling D M , et al. WHO classification of tumors of haematopoietic and lymphoid tissues. 4th ed. Lyon: WHO Press, 2008: 110-123.
|
|
|
| [9] |
Arber D A, Orazi A, Hasserjian R , et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood, 2016,127(20):2391-2405.
|
|
|
| [10] |
Bj?rkholm M, Ohm L, Eloranta S , et al. Success story of targeted therapy in chronic myeloid leukemia: a population-based study of patients diagnosed in Sweden from 1973 to 2008. J Clin Oncol, 2011,29(18):2514-2520.
doi: 10.1200/JCO.2011.34.7146
|
|
|
| [11] |
Saussele S, Richter J, Guilhot J , et al. Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial. Lancet Oncol, 2018,19(6):747-757.
|
|
|
| [12] |
Soverini S, Hochhaus A, Nicolini F E , et al. BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood, 2011,118(5):1208-1215.
doi: 10.1182/blood-2010-12-326405
|
|
|
| [13] |
Winer E S, Stone R M . Novel therapy in acute myeloid leukemia (AML): moving toward targeted approaches. Ther Adv Hematol, 2019, Doi: 10.1177/2040620719860645.
doi: 10.1177/2040620719860645
|
|
|
| [14] |
秦亚溱, 李金兰, 主鸿鹄 , 等. 实时定量R T-PC R技术测定初治白血病患者常见融合基因转录子水平及其标准化的探讨. 中华血液学杂志, 2007,28(7):353-357.
|
|
|
| [14] |
Qin Y Z, Li J L, Zhu H H , et al. Detection of common fusion transcript levels in untreated leukemia patients by real-time quantitative RT-PCR technique. Chinese Journal of Hematology, 2007,28(7):353-357.
|
|
|
| [15] |
Hughes T, Deininger M, Hochhaus A , et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood, 2006,108(1):28-37.
|
|
|
| [16] |
秦亚溱, 马道新, 王云贵 , 等. 转换国际标准化的 BCR-ABL(P210)转录本水平的转换系数多中心再确认研究. 中华血液学杂志, 2015,36(10):814-817.
|
|
|
| [16] |
Qin Y Z, Ma D X, Wang Y G , et al. A multicenter study on the revalidation of validated conversion factor for the conversion of BCR-ABL (P210) transcript levels to the international scale in chronic myeloid leukemia. Chinese Journal of Hematology, 2015,36(10):814-817.
|
|
|
| [17] |
Alvarnas J C, Brown P A, Aoun P , et al. Acute lymphoblastic leukemia,Version 2. 2015: clinical practice guidelines in oncology. Journal of The National Comprehensive Cancer Network, 2015,13(10):1240-1279.
|
|
|
| [18] |
Yin J A , O’Brien M A, Hills R K , et al. Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trial. Blood, 2012,120(14):2826-2835.
doi: 10.1182/blood-2012-06-435669
|
|
|
| [19] |
Zhu H H, Zhang X H, Qin Y Z , et al. MRD-directed risk stratification treatment may improve outcomes of t(8;21) AML in the first complete remission: results from the AML05 multicenter trial. Blood, 2013,121(20):4056-4062.
doi: 10.1182/blood-2012-11-468348
|
|
|
| [20] |
Qin Y Z, Wang Y, Xu L P , et al. The dynamics of RUNX1-RUNX1T1 transcript levels after allogeneic hematopoietic stem cell transplantation predict relapse in patients with t(8;21) acute myeloid leukemia. J Hematol Oncol, 2017,10(1):44.
|
|
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
| |
Shared |
|
|
|
|
| |
Discussed |
|
|
|
|
